US · Healthcare · Biotechnology
EPS came in at 1.63 against a street estimate of 1.80 — a miss of 9.4%.
Analysts rate Ligand Pharmaceuticals Incorporated a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $323.30.
| Fund | Stake |
|---|---|
| BlackRock Inc | 14.78% |
| Vanguard Portfolio Management, LLC | 5.49% |
| HHG PLC | 5.04% |
| Vanguard Capital Management, LLC | 4.23% |
| Amvescap Plc. | 4.11% |
| State Street Corp | 3.89% |
| Congress Asset Management Company, LLP | 3.29% |
| FMR Inc | 2.97% |
| Document | Date |
|---|---|
| Material agreement · Q3 2026 | 2026-07-14 |
| Material agreement · Q2 2026 | 2026-06-25 |
| Material agreement · Q2 2026 | 2026-06-22 |
| Board / officer change · Q2 2026 | 2026-06-09 |
| Quarterly report · Q1 2026 | 2026-05-08 |
| Proxy statement · Q4 2025 | 2026-04-21 |
| Annual report FY2025 | 2026-02-27 |
| Quarterly report · Q3 2025 | 2025-11-07 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Ligand Pharmaceuticals Incorporated — free to start.
Google PlayApp StoreData updated 2026-08-05.